Nanologica
5.7 SEK +7.55%1 investor is following this company
Nanologica is a biotechnology company that develops, manufactures, and sells nanoporous silica particles for life science applications. The company has two business areas: chromatography, which is an analysis and purification technique in the pharmaceutical industry used, for example in insulin, and drug development where the company develops an inhalation platform to deliver drugs locally in the lung. Nanologica was founded in 2004 and is headquartered in Södertälje.
Revenue
1.44M
EBIT %
-4,858.33 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
NICA
Daily low / high price
5.4 / 5.98
SEK
Market cap
251.82M SEK
Turnover
192.61K SEK
Volume
34K
Financial calendar
General meeting
16.05.2024
Interim report
05.07.2024
Interim report
25.10.2024
Annual report
07.02.2025
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Flerie Invest AB | 41.2 % | 41.2 % |
Swedbank Robur Microcap | 6.4 % | 6.4 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Redeye: Nanologica Q1 2024 - Mixed start of the year
Interim Report Q1 2024 Nanologica AB (publ)
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools